Waldenstrom macroglobulinemia

Common Name(s)

Waldenstrom macroglobulinemia

Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy, fever, Raynaud's phenomenon, and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition. Treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Waldenstrom macroglobulinemia" for support, advocacy or research.

International Waldenstrom's Macroglobulinemia Foundation

To offer mutual support and encouragement to the Waldenstrom's macroglobulinemia community and others with an interest in the disease. To provide information and educational programs that address patients' concerns. To promote and support research leading to better treatments and ultimately a cure.

Last Updated: 16 Jul 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Waldenstrom macroglobulinemia" for support, advocacy or research.

International Waldenstrom's Macroglobulinemia Foundation

To offer mutual support and encouragement to the Waldenstrom's macroglobulinemia community and others with an interest in the disease. To provide information and educational programs that address patients' concerns. To promote and support research leading to better treatments and ultimately a cure.

http://www.iwmf.com

Last Updated: 16 Jul 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Waldenstrom macroglobulinemia" returned 100 free, full-text research articles on human participants. First 3 results:

Proteasome inhibitors in Waldenström macroglobulinemia.
 

Author(s): Steven P Treon

Journal: Blood. 2013 Nov;122(19):3243-4.

 

Last Updated: 8 Nov 2013

Go To URL
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
 

Author(s): Meletios A Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld

Journal: Blood. 2013 Nov;122(19):3276-82.

 

In this phase 2 multicenter trial, we evaluated the activity of bortezomib, dexamethasone, and rituximab (BDR) combination in previously untreated symptomatic patients with Waldenström macroglobulinemia (WM). To prevent immunoglobulin M (IgM) "flare," single agent bortezomib (1.3 ...

Last Updated: 8 Nov 2013

Go To URL
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
 

Author(s): Guang Yang, Yangsheng Zhou, Xia Liu, Lian Xu, Yang Cao, Robert J Manning, Christopher J Patterson, Sara J Buhrlage, Nathanael Gray, Yu-Tzu Tai, Kenneth C Anderson, Zachary R Hunter, Steven P Treon

Journal: Blood. 2013 Aug;122(7):1222-32.

 

Myeloid differentiation factor 88 (MYD88) L265P somatic mutation is highly prevalent in Waldenström macroglobulinemia (WM) and supports malignant growth through nuclear factor κB (NF-κB). The signaling cascade(s) by which MYD88 L265P promotes NF-κB activation in WM remain unclear. ...

Last Updated: 16 Aug 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Waldenstrom macroglobulinemia" returned 13 free, full-text review articles on human participants. First 3 results:

Novel treatment options for Waldenström macroglobulinemia.
 

Author(s): Houry Leblebjian, Amit Agarwal, Irene Ghobrial

Journal: Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2():S310-6.

 

Waldenström macroglobulinemia (WM), first described by Jan Waldenström in 1944, is a lymphoplasmacytic lymphoma characterized by the presence of an immunoglobulin M monoclonal gammopathy in the blood and monoclonal small lymphocytes and lymphoplasmacytoid cells in the bone marrow. ...

Last Updated: 2 Dec 2013

Go To URL
The bone marrow microenvironment in Waldenström macroglobulinemia.
 

Author(s): Amit Agarwal, Irene M Ghobrial

Journal: Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):218-21.

 

Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized by widespread involvement of the bone marrow (BM). The BM microenvironment serves as not only a site for disease involvement, but it also appears that the interaction of WM cells with the BM is essential ...

Last Updated: 13 May 2013

Go To URL
Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
 

Author(s): Robert A Kyle, Terry M Therneau, Angela Dispenzieri, Shaji Kumar, Joanne T Benson, Dirk R Larson, L Joseph Melton, S Vincent Rajkumar

Journal: Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):184-6.

 

Monoclonal gammopathy of undetermined significance of the immunoglobulin M class was diagnosed in 213 patients at the Mayo Clinic, 29 (14%) of whom developed lymphoma, Waldenström macroglobulinemia, or a related disorder over 1567 person-years of follow-up. The cumulative probability ...

Last Updated: 13 May 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenström Macroglobulinemia; Lymphoplasmacytic Lymphoma; Splenic Marginal Zone Lymphoma

 

Last Updated: 30 Nov 2007

Go to URL
Randomised Trial in Waldenstrom's Macroglobulinaemia
 

Status: Recruiting

Condition Summary: Waldenstrom's Macroglobulinaemia

 

Last Updated: 3 Dec 2014

Go to URL
An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenström Macroglobulinemia (WM)

 

Last Updated: 19 Sep 2014

Go to URL